Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 116 of the 117 references it cites were found in a registry or an index; 9 of the 58 sources its claims cite were checked for support.
Abstract
Alzheimer's disease (AD) is characterized by progressive cognitive decline associated with a featured neuropathology (neuritic plaques and neurofibrillary tangles). Several studies have implicated oxidative damage to DNA, DNA repair, and altered cell-cycle regulation in addition to cell death in AD post-mitotic neurons. However, there is a lack of studies that systematically assess those biological processes in patients with AD neuropathology but with no evidence of cognitive impairment. We evaluated markers of oxidative DNA damage (8-OHdG, H2AX), DNA repair (p53, BRCA1, PTEN), and cell-cycle (Cdk1, Cdk4, Cdk5, Cyclin B1, Cyclin D1, p27Kip1, phospho-Rb and E2F1) through immunohistochemistry and cell death through TUNEL in autopsy hippocampal tissue samples arrayed in a tissue microarray (TMA) composed of three groups: I) "clinical-pathological AD" (CP-AD)--subjects with neuropathological AD (Braak ≥ IV and CERAD = B or C) and clinical dementia (CDR ≥ 2, IQCODE>3.8); II) "pathological AD" (P-AD)--subjects with neuropathological AD (Braak ≥ IV and CERAD = B or C) and without cognitive impairment (CDR 0, IQCODE<3.2); and III) "normal aging" (N)--subjects without neuropathological AD (Braak ≤ II and CERAD 0 or A) and with normal cognitive function (CDR 0, IQCODE<3.2). Our results show that high levels of oxidative DNA damage are present in all groups. However, significant reductions in DNA repair and cell-cycle inhibition markers and increases in cell-cycle progression and cell death markers in subjects with CP-AD were detected when compared to both P-AD and N groups, whereas there were no significant differences in the studied markers between P-AD individuals and N subjects. This study indicates that, even in the setting of pathological AD, healthy cognition may be associated with a preserved repair to DNA damage, cell-cycle regulation, and cell death in post-mitotic neurons.
Overview
CoChat Summary
TL;DR
In autopsy hippocampal tissue, subjects with AD neuropathology and clinical dementia (CP-AD) showed reduced DNA-repair/cell-cycle-inhibition markers and increased cell-cycle-progression and cell-death markers compared with both pathological AD without cognitive impairment (P-AD) and normal aging (N). P-AD subjects were largely indistinguishable from N subjects, suggesting preserved DNA repair and cell-cycle control may accompany resilient cognition despite AD pathology.
Key findings
- Oxidative DNA damage markers were elevated in CP-AD versus N: nuclear 8-OHdG median 25 vs 15 (Dunn p=0.0145) and nuclear H2AX median 20 vs 7 (p=0.0001); high damage was present in all groups.
- Nuclear DNA-repair markers were lower in CP-AD than in P-AD and N: p53 median 7 vs 14 and 15 (CP-AD vs N p<0.0001; CP-AD vs P-AD p=0.0222), and PTEN median 25 vs 31 and 27 (CP-AD vs P-AD p=0.0003; CP-AD vs N p=0.0093).
- Cell-cycle progression markers (Cdk4, cyclin D, phospho-Rb, E2F1, Cdk1, cyclin B) were higher in CP-AD than in P-AD and N, while inhibitors p27 and Cdk5 were lower in CP-AD; apoptosis was higher in CP-AD (median 20) than P-AD (3.5) and N (0).
- Hierarchical clustering separated all CP-AD samples from a combined P-AD + N cluster with 100% bootstrap support; P-AD and N showed no significant differences for the studied markers.
Methods
- Post-mortem hippocampal CA1 tissue from the Brain Bank of the Brazilian Aging Brain Study Group was arrayed in a tissue microarray; groups were CP-AD (neuropathological AD plus dementia), P-AD (neuropathological AD without cognitive impairment), and N (normal aging), with Table 1 listing 19 CP-AD, 12 P-AD, and 31 N subjects (TMA construction text says 18 CP-AD).
- Immunohistochemistry assessed oxidative DNA damage (8-OHdG, H2AX), DNA repair (p53, BRCA1, PTEN, phospho-AKT), and cell-cycle markers (Cdk1, Cdk4, Cdk5, cyclin B1, cyclin D1, p27Kip1, phospho-Rb, E2F1); TUNEL assessed cell death.
- Nuclear and cytoplasmic positivity/intensity were scored semiquantitatively; group comparisons used Kruskal-Wallis with Dunn’s tests, and hierarchical clustering used Pearson correlation with average linkage and bootstrap support.
Limitations
- The paper states that additional studies are required to better understand pathogenic mechanisms, especially early AD stages, and to uncover and validate resilience biomarkers.
- Evident from the text: small group sizes (19 CP-AD, 12 P-AD, 31 N in Table 1), analysis restricted to hippocampal CA1 tissue microarray cores, and semiquantitative manual immunohistochemistry scoring.
- Evident from the text: cross-sectional autopsy design cannot establish causality; the authors argue PMI effects are unlikely because groups did not differ significantly in PMI and intervals were under 24 hours.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
8 Valid · 0 Not valid · 34 Not checked · 56 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Among individuals who showed no overt evidence of cognitive impairment in the final assessment prior to death, post-mortem studies showed a significant proportion of subjects with neuropathological diagnoses of AD”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Introduction
What the sources say
- Not checked yetcites [9] J Price, 1999, Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease, Ann Neurol source
- Supportedcites [10] JL Price, 2009, Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease, Neurobiol Aging source
The Abstract (Results) reports that about 40% of nondemented individuals met some neuropathological criteria for AD, or about 20% under strict criteria, and that neither group had measurable cognitive impairment before death. The Results (Comparison of npAD and no-npAD cases) specifically refer to their last clinical assessment before death. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genes involved in oxidative stress and in DNA damage/repair were found to be coupled with AD neuropathology.”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Introduction
What the sources say
- Supportedcites [24] AR Silva, 2012, Transcriptional alterations related to neuropathology and clinical manifestation of Alzheimer’s disease, PLoS One source
The Abstract states that 'genes involved in energy metabolism, oxidative stress, DNA damage/repair, senescence, and transcriptional regulation were implicated with the neuropathology of AD,' directly matching the claim. The Discussion (AD neuropathology-related gene set) and Results (Gene Expression Profile Related to AD Pathology) reinforce this, listing negative regulation of reactive oxygen species metabolic process and DNA synthesis involved in DNA repair among the overrepresented categories in Braak >=IV / CERAD B-C subjects versus no-pathology controls. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent studies have reported alterations in DNA repair proteins (cell-cycle checkpoint proteins and tumor suppressors) of pathways involved in the repair of oxidative stress-induced lesions in patients with AD [28], [79].”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Discussion
What the sources say
- Partly supportedcites [28] P Katsel, 2013, Cycle checkpoint abnormalities during dementia: a plausible association with the loss of protection against oxidative stress in Alzheimer’s disease, PLoS One sourceExperimental — accuracy not yet measured
The paper does report alterations in cell-cycle checkpoint proteins and tumor suppressors in AD brain: the Introduction lists prior reports of changed CCL marker expression (including BRCA1, p16, p27, RB) in cortical neurons of persons with AD, and its own Results/Discussion show upregulated MDM4, ATM and ATR with declining TIGAR in STG of AD-dementia cases, described as an activated 'ATM signaling and DNA damage response network'. However, the source's own 'Recent studies have reported' sentence (Abstract > Background) credits checkpoint proteins and tumor suppressors such as ATM and p53 with controlling glycolysis and oxidative metabolism in cancer and states 'their involvement in AD remains uncertain', and the Discussion frames the DNA-damage response as repair of double-strand breaks, with the oxidative-stress link only 'a plausible association' (ATM 'may' link ROS damage to cell-cycle reactivation, loss of TIGAR-mediated protection). So the claim's assertion that these pathways repair oxidative stress-induced lesions in AD patients is presented more firmly than the source, which hedges that connection. (LLM, conf=0.70)
- Not checked yetcites [79] Bucholtz N, Demuth I (2013) DNA-repair in mild cognitive impairment and Alzheimer’s disease. DNA Repair (Amst). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Yang et al. [34] showed that in brains of people who died with MCI, the percentage of hippocampal neurons positive for cell-cycle proteins (PCNA, cyclin D and cyclin B) was very close to that found in individuals who died in advanced stages of AD (demented).”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Discussion
What the sources say
- Partly supportedcites [34] Y Yang, 2003, Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease, J Neurosci sourceExperimental — accuracy not yet measured
Yang et al. (2003) do report the similarity the claim rests on: the Abstract and the Cell counts section state that in hippocampus the percentages of cell cycle-immunopositive neurons in MCI 'were similar to those found in the AD cases' and far above controls (Table 2: cyclin D 5.2% vs 6.3%, PCNA 7.0% vs 7.1%), and cyclin B 'showed comparable levels of staining in both MCI and AD'. However, the comparison group is not characterized as advanced-stage AD: the Fig. 2 legend describes the AD material as 'subjects who died with mild to moderate AD', and Table 1 shows only 5 of 9 AD cases at Braak V-VI (mean MMSE 18.2, range 3-25), so the 'died in advanced stages of AD' qualifier is not what this source states. Additionally, cyclin B is reported only qualitatively as comparable staining (Fig. 3), not as a tabulated percentage of positive hippocampal neurons like PCNA and cyclin D. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“recent data have suggested a crucial role for Cdk5 as a cell-cycle suppressor in post-mitotic neurons.”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Discussion
What the sources say
- Supportedcites [103] J Zhang, 2010, Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex, J Neurosci source
The INTRODUCTION states outright that 'Cdk5 also plays a crucial role in neuronal cell cycle control,' with loss of Cdk5 causing failure of cell cycle suppression in Cdk5−/− neurons, and frames the work as understanding 'the factors that maintain a mammalian neuron in its post-mitotic state.' The Abstract calls Cdk5 'a potent cell cycle suppressor' and the DISCUSSION reiterates that 'nuclear Cdk5 acts as a cell cycle suppressor both in vivo and in vitro.' The hedged 'recent data have suggested' is therefore supported by a source making the point with equal or greater confidence; the only mild caveat is that the paper's own new experiments are in N2a cells and E14.5 embryonic progenitors, with the post-mitotic-neuron evidence resting on its prior work (Cicero and Herrup, 2005; Zhang et al., 2008) that this paper reports and relies on. (LLM, conf=0.88)
- Not checked yetcites [104] J Zhang, 2012, Cdk5 levels oscillate during the neuronal cell cycle: Cdh1 ubiquitination triggers proteosome-dependent degradation during S-phase, J Biol Chem source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
66 more claims · 1 with their cited sources checked
Create a free account to see all 98 claims and to verify the 49 references still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 13
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“elevated phosphorylated histone γH2AX (H2A histone family member X) levels have been reported in the hippocampus and lymphocytes from AD patients, indicating an active DNA damage response [230,231].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [230]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Abstract
“there were no significant differences in the studied markers between P-AD individuals and N subjects.”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Results > Oxidative DNA Damage
“| Cyclin D | 7 (0–14) | 9 (0–15) | 0 (0–15) | 0.0072* | 0.3813 | 0.269 | 0.0056* |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Materials and Methods > Tissue Samples and Neuropathological/Cognitive Assessment
“| N1 | M | 80 | 3 | 0 | 0 | 19.7 |”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Materials and Methods > Tissue Samples and Neuropathological/Cognitive Assessment
“31 subjects without neuropathological AD (Braak≤II and CERAD 0 or A) and with normal cognitive function”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Women, n (%) | 16 (84.2) | 7 (61.5) | 16 (51.6) | 0.064b |”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Results
Reported 61.5 · recomputed 58.333333
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“hippocampal samples (CA1 region) from 62 subjects (18 CP-AD, 12 P-AD, and 31 N)”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Materials and Methods > Construction of Tissue Microarray
Reported 62 · recomputed 61
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Materials and Methods > Tissue Samples and Neuropathological/Cognitive Assessment
“| CP-AD1 | F | 98 | 3 | B | 2 | 15.1 |”
§ Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease > Materials and Methods > Tissue Samples and Neuropathological/Cognitive Assessment
“19 subjects with neuropathological AD (Braak≥IV and CERAD = B or C) and clinical dementia”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496 · cited 1×
“Among the studied biomarkers, BRCA1 is associated with a spectrum of functions related to the preservation of genome stability, such as the repair of oxidative damage to DNA [84,85].”
BackgroundRetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Neurofibrillary tangles (NFTs) and neuritic plaques (NPs) were assessed by a skilled neuropathologist in accordance with the Braak stage system [55] and the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) [56], respectively.”
MethodThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115 · cited 1×
“Notably, phosphorylated Akt may enhance cell survival by blocking the function of proteins and apoptotic processes [95].”
BackgroundGlobal prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332 · cited 1×
“Alzheimer’s disease (AD) is the most frequent cause of dementia in the elderly, accounting for approximately 70% of dementia cases [1,2].”
BackgroundMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 4×
“Based on pathological and clinical criteria, subjects were categorized into three groups: I) 19 subjects with neuropathological AD (Braak$IV and CERAD=B or C) and clinical dementia (CDR$2, IQCODE.3.8), termed ‘‘clinical-pathological AD’’ (CPAD); II) 12 subjects with neuropathological AD (Braak$IV and CERAD=B or C) and…”
MethodInfluentialTM4: a free, open-source system for microarray data management and analysis
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003) · BioTechniques · doi:10.2144/03342mt01 · Cited by 4,837
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Gene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874 · cited 1×
“It is generally accepted that accumulation of DNA damage and the impairment of its repair mechanism is a prominent feature of aging in the CNS [80], and the impairment of this process is believed to be exacerbated in dementia and AD [81–83].”
BackgroundEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Jorm, A. F. (1994) · Psychological Medicine · doi:10.1017/s003329170002691x · Cited by 1,204 · cited 3×
“Based on pathological and clinical criteria, subjects were categorized into three groups: I) 19 subjects with neuropathological AD (Braak$IV and CERAD=B or C) and clinical dementia (CDR$2, IQCODE.3.8), termed ‘‘clinical-pathological AD’’ (CPAD); II) 12 subjects with neuropathological AD (Braak$IV and CERAD=B or C) and…”
MethodInfluentialThe role of mitochondria in aging
Bratic, A., & Larsson, N.-G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64125 · Cited by 1,087 · cited 1×
“We observed that biomarkers of oxidative damage in DNA are highly expressed in all groups in this study, which is expected because our population has an average age of 85 and accumulation of such damages occurs during aging [66].”
BackgroundFrequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059 · cited 1×
“Molecular neuroimaging and CSF biomarker studies have demonstrated that 20–40% of older subjects with no cognitive impairment display a significant accumulation of Ab in the brain [11–15].”
BackgroundOxidative damage to mitochondrial DNA is increased in Alzheimer’s disease
Mecocci, P., MacGarvey, U., & Beal, M. F. (1994) · Annals of Neurology · doi:10.1002/ana.410360510 · Cited by 1,037 · cited 1×
“Different biomarkers of oxidative damage to DNA have been assessed in AD brains, but the most popular for assays is the base 8-hydroxy-2-deoxyguanosine, which is increased in AD brain samples compared with age-matched controls [26,27].”
BackgroundThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979 · cited 1×
“PTEN may have functions in the maintenance of genomic stability mediated at least in part by PI3K-independent mechanisms [87,88].”
BackgroundAge, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900 · cited 1×
“In addition, more recent large-scale epidemiological studies have shown discordance of cognition with AD pathology [16–20].”
BackgroundDynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80503-6 · Cited by 900 · cited 1×
“Among the studied biomarkers, BRCA1 is associated with a spectrum of functions related to the preservation of genome stability, such as the repair of oxidative damage to DNA [84,85].”
BackgroundFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Molecular neuroimaging and CSF biomarker studies have demonstrated that 20–40% of older subjects with no cognitive impairment display a significant accumulation of Ab in the brain [11–15].”
BackgroundPeters, A., & Vaughan, D. W. (1981) · Aging and Cell Structure · doi:10.1007/978-1-4684-3929-8_1 · Cited by 888
Cognitive Reserve and Alzheimer Disease
Stern, Y. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213815.20177.19 · Cited by 838 · cited 1×
“Although the neurobiological basis of such discordance between pathology and clinical outcome is not yet understood, there may be compensatory mechanisms that protect such individuals against the clinical emergence of AD because they carry a high burden of histopathological lesions but can support them without cogniti…”
Background(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-272_3 · Cited by 801
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757 · cited 1×
“We observed that 8-OHdG levels are significantly higher in CP-AD individuals than in subjects with normal aging (N), as demonstrated by others in hippocampus utilizing immunohistochemistry [67] and in various cortical regions utilizing other methodologies [26,68–71].”
MethodUbiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748 · cited 1×
“PTEN may have functions in the maintenance of genomic stability mediated at least in part by PI3K-independent mechanisms [87,88].”
BackgroundRNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease
Nunomura, A., Perry, G., Pappolla, M. A., Wade, R., Hirai, K., Chiba, S., & Smith, M. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-06-01959.1999 · Cited by 722 · cited 1×
“We observed that 8-OHdG levels are significantly higher in CP-AD individuals than in subjects with normal aging (N), as demonstrated by others in hippocampus utilizing immunohistochemistry [67] and in various cortical regions utilizing other methodologies [26,68–71].”
MethodThe prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721 · cited 12×
“Regarding nuclear staining, pyramidal neurons from the hippocampus of CP-AD individuals demonstrated higher expression levels of Cdk4, cyclin D, phospho-Rb, E2F1, Cdk1, and cyclin B than did those from either P-AD or N subjects (Figure 3A, 3C, 3E, 3G, 3I, and 3K; Table 4; Figures S9–S14).”
BackgroundInfluentialNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 1×
“Among individuals who showed no overt evidence of cognitive impairment in the final assessment prior to death, post-mortem studies showed a significant proportion of subjects with neuropathological diagnoses of AD [9,10].”
BackgroundOxidative stress hypothesis in Alzheimer’s disease: a reappraisal
Praticò, D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.09.001 · Cited by 606 · cited 1×
“DNA injury due to oxidative stress has been confirmed in various studies to have a role in the pathogenesis of AD [25].”
BackgroundNeuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596 · cited 1×
“Some studies have reported preserved neuronal numbers and synaptic densities in the hippocampus in ‘‘preclinical/resilient AD’’ compared with normal and clinical AD cases [62,108,109].”
BackgroundEctopic Cell Cycle Proteins Predict the Sites of Neuronal Cell Death in Alzheimer’s Disease Brain
Busser, J., Geldmacher, D. S., & Herrup, K. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02801.1998 · Cited by 543 · cited 1×
“For instance: 1) our findings that cell-cycle-progression regulators, such as Cdk4, Cdk1, cyclin D, cyclin B, phospho-Rb, and E2F1, are upregulated in CP-AD compared with N are consistent with other studies that indicate that cell-cycle molecules are upregulated in AD neurons [34,37,40,41,46,102]; 2) our finding that…”
ResultHutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Lyras, L., Cairns, N. J., Jenner, A., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052061.x · Cited by 531 · cited 1×
“We observed that 8-OHdG levels are significantly higher in CP-AD individuals than in subjects with normal aging (N), as demonstrated by others in hippocampus utilizing immunohistochemistry [67] and in various cortical regions utilizing other methodologies [26,68–71].”
MethodCell cycle regulation in the postmitotic neuron: oxymoron or new biology?
Herrup, K., & Yang, Y. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2124 · Cited by 507 · cited 1×
“Neurodegeneration in AD can take several years, and neuronal death is not the result of a single acute insult, but is likely the consequence of many triggers that induce compensatory responses for a long period of time until there is a loss of the capacity to maintain homeostasis [107].”
BackgroundNeuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease
Yang, Y., Mufson, E. J., & Herrup, K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02557.2003 · Cited by 483 · cited 4×
“There is also growing evidence for the association between DNA damage and increased expression of cell-cycle markers in AD [34,38].”
BackgroundResultInfluentialIncreased Nuclear DNA Oxidation in the Brain in Alzheimer's Disease
Gabbita, S. P., Lovell, M. A., & Markesbery, W. R. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052034.x · Cited by 478 · cited 1×
“We observed that 8-OHdG levels are significantly higher in CP-AD individuals than in subjects with normal aging (N), as demonstrated by others in hippocampus utilizing immunohistochemistry [67] and in various cortical regions utilizing other methodologies [26,68–71].”
MethodThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.09.172 · Cited by 476 · cited 1×
“Individuals who have evidence of abundant AD pathology but do not meet clinical criteria for mild cognitive impairment (MCI) or dementia, thus preserving their cognitive functioning, have been described by a range of allied concepts such as ‘‘pathological aging’’, ‘‘preclinical AD’’, ‘‘asymptomatic AD’’, and ‘‘resilie…”
Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.
McShea, A., Harris, P. L. R., Webster, K. R., Wahl, A. F., & Smith, M. A. (1997) · Europe PMC (PubMed Central) · Cited by 467
Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459 · cited 2×
“Consequently, these results have led to intensive research on alterations in DNA repair proteins involved in the repair of such lesions in patients with AD, including p53, PTEN and BRCA1 [28–33].”
ResultIncreased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease
Wang, J., Xiong, S., Xie, C., Markesbery, W. R., & Lovell, M. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03053.x · Cited by 451 · cited 1×
“We observed that 8-OHdG levels are significantly higher in CP-AD individuals than in subjects with normal aging (N), as demonstrated by others in hippocampus utilizing immunohistochemistry [67] and in various cortical regions utilizing other methodologies [26,68–71].”
MethodVincent, I., Jicha, G., Rosado, M., & Dickson, D. W. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-10-03588.1997 · Cited by 444 · cited 1×
“For instance: 1) our findings that cell-cycle-progression regulators, such as Cdk4, Cdk1, cyclin D, cyclin B, phospho-Rb, and E2F1, are upregulated in CP-AD compared with N are consistent with other studies that indicate that cell-cycle molecules are upregulated in AD neurons [34,37,40,41,46,102]; 2) our finding that…”
ResultBennett, D. A., Schneider, J. A., Aggarwal, N. T., Arvanitakis, Z., Shah, R. C., Kelly, J. F., Fox, J. H., Cochran, E. J., Arends, D., Treinkman, A. D., et al. (2006) · Neuroepidemiology · doi:10.1159/000096129 · Cited by 414
Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias
Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W., Masliah, E., Terry, R., Hill, L. R., Lessin, P., & Thal, L. J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210060013 · Cited by 409 · cited 1×
“Although there is evidence showing that the majority of persons identified as having clinical AD meet the neuropathological criteria for AD [4–8], the correlation between those neuropathological lesions and cognition is relatively poor.”
BackgroundNuclear PTEN controls DNA repair and sensitivity to genotoxic stress
Bassi, C., Ho, J., Srikumar, T., Dowling, R. J. O., Gorrini, C., Miller, S. J., Mak, T. W., Neel, B. G., Raught, B., & Stambolic, V. (2013) · Science · doi:10.1126/science.1236188 · Cited by 403 · cited 1×
“[91] demonstrated that nuclear PTEN is involved in DNA repair, and cells without nuclear PTEN are more sensitive to DNA damage.”
BackgroundAnderson, A., Su, J., & Cotman, C. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-05-01710.1996 · Cited by 389 · cited 1×
“Some authors have reasoned that the presence of DNA breaks by oxidative damage could be influenced by the post-mortem interval, but the presence of such an effect has not been clearly demonstrated [75–78].”
BackgroundGearing, M., Mirra, S. S., Hedreen, J. C., Sumi, S. M., Hansen, L. A., & Heyman, A. (1995) · Neurology · doi:10.1212/wnl.45.3.461 · Cited by 380
“Preclinical” AD revisited: Neuropathology of cognitively normal older adults
Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000) · Neurology · doi:10.1212/wnl.55.3.370 · Cited by 369
Defective DNA Repair and Neurodegenerative Disease
Rass, U., Ahel, I., & West, S. C. (2007) · Cell · doi:10.1016/j.cell.2007.08.043 · Cited by 358 · cited 1×
“It is generally accepted that accumulation of DNA damage and the impairment of its repair mechanism is a prominent feature of aging in the CNS [80], and the impairment of this process is believed to be exacerbated in dementia and AD [81–83].”
BackgroundDragunow, M., Faull, R. L. M., Lawlor, P., Beilharz, E. J., Singleton, K., Walker, E. B., & Mee, E. (1995) · NeuroReport · doi:10.1097/00001756-199505090-00026 · Cited by 342
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327
Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Townsend, M., Mehta, T., & Selkoe, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610390200 · Cited by 318 · cited 1×
“If Akt is not phosphorylated, GSK3-b remains active [93] and is described as responsible for events related to AD pathology, including the hyperphosphorylation of Tau [94].”
BackgroundCell cycle markers in the hippocampus in Alzheimer's disease
Nagy, Z., Esiri, M. M., Cato, A.-M., & Smith, A. D. (1997) · Acta Neuropathologica · doi:10.1007/s004010050665 · Cited by 318 · cited 1×
“Furthermore, changes in the expression of cell-cycle proteins (cyclins D [34] and B [34–36], Cdk4 [37], Cdk1 [38], p27 [39], E2F1 [40], and phosphorylated retinoblastoma protein [41]) have been noted in neurons of post-mortem brain specimens from persons with AD.”
BackgroundHippocampal neurons in pre-clinical Alzheimer's disease.
West, M. J., Kawas, C. H., Stewart, W. F., Rudow, G. L., & Troncoso, J. C. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.005 · Cited by 317 · cited 1×
“Some studies have reported preserved neuronal numbers and synaptic densities in the hippocampus in ‘‘preclinical/resilient AD’’ compared with normal and clinical AD cases [62,108,109].”
BackgroundCulmsee, C., Zhu, X., Yu, Q.-S., Chan, S. L., Camandola, S., Guo, Z., Greig, N. H., & Mattson, M. P. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00220.x · Cited by 313
Weissman, L., Jo, D.-G., Sorensen, M. M., de Souza-Pinto, N. C., Markesbery, W. R., Mattson, M. P., & Bohr, V. A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm605 · Cited by 299 · cited 1×
“Moreover, decreased activity of proteins involved with DNA repair has been reported in MCI subjects [105,106].”
BackgroundVillemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, T. F., Currie, J., Chan, S. G., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.008 · Cited by 292 · cited 1×
“Molecular neuroimaging and CSF biomarker studies have demonstrated that 20–40% of older subjects with no cognitive impairment display a significant accumulation of Ab in the brain [11–15].”
BackgroundMechanisms of Neuronal Death in Alzheimer's Disease
Cotman, C. W., & Su, J. H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00878.x · Cited by 275 · cited 1×
“It is generally accepted that accumulation of DNA damage and the impairment of its repair mechanism is a prominent feature of aging in the CNS [80], and the impairment of this process is believed to be exacerbated in dementia and AD [81–83].”
BackgroundAneuploidy and DNA Replication in the Normal Human Brain and Alzheimer's Disease
Mosch, B., Morawski, M., Mittag, A., Lenz, D., Tarnok, A., & Arendt, T. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0379-07.2007 · Cited by 271 · cited 1×
“Furthermore, changes in the expression of cell-cycle proteins (cyclins D [34] and B [34–36], Cdk4 [37], Cdk1 [38], p27 [39], E2F1 [40], and phosphorylated retinoblastoma protein [41]) have been noted in neurons of post-mortem brain specimens from persons with AD.”
BackgroundIncreased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment
Wang, J., Markesbery, W. R., & Lovell, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03615.x · Cited by 260 · cited 1×
“Different biomarkers of oxidative damage to DNA have been assessed in AD brains, but the most popular for assays is the base 8-hydroxy-2-deoxyguanosine, which is increased in AD brain samples compared with age-matched controls [26,27].”
BackgroundOxidative stress in vascular dementia and Alzheimer’s disease: a common pathology
Bennett, S., Grant, M. M., & Aldred, S. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1041 · Cited by 254 · cited 1×
“Among these factors, oxidative stress has been shown to be involved in AD pathogenesis [64,65].”
BackgroundCognitive Reserve and Alzheimer’s Disease
Xu, W., Yu, J.-T., Tan, M.-S., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8720-y · Cited by 240
Pei, J.-J., Grundke-Iqbal, I., Iqbal, K., Bogdanovic, N., Winblad, B., & Cowburn, R. F. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00296-0 · Cited by 226 · cited 1×
“Another protein (Cdk5), which is not associated with the cell-cycle, has been suggested as a cell-cycle suppressor in post-mitotic neurons [42,43], with ectopic subcellular redistribution in neurons of cases affected with AD [44,45].”
BackgroundRoe, C. M., Mintun, M. A., D’Angelo, G., Xiong, C., Grant, E. A., & Morris, J. C. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1467 · Cited by 215 · cited 1×
“Although the neurobiological basis of such discordance between pathology and clinical outcome is not yet understood, there may be compensatory mechanisms that protect such individuals against the clinical emergence of AD because they carry a high burden of histopathological lesions but can support them without cogniti…”
BackgroundGiovanni, A., Keramaris, E., Morris, E. J., Hou, S. T., O'Hare, M., Dyson, N., Robertson, G. S., Slack, R. S., & Park, D. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.16.11553 · Cited by 205
Iacono (2009) · doi:10.1212/wnl.0b013e3181b01077 · Cited by 203
Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients
Mullaart, E., Boerrigter, M. E. T. I., Ravid, R., Swaab, D. F., & Vijg, J. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90542-8 · Cited by 201 · cited 1×
“It is generally accepted that accumulation of DNA damage and the impairment of its repair mechanism is a prominent feature of aging in the CNS [80], and the impairment of this process is believed to be exacerbated in dementia and AD [81–83].”
BackgroundSperling, R. A., Aisen, P. S. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J. A., Montine, T. J., et al. (2011) · Cited by 197
White, L. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1178 · Cited by 193 · cited 1×
“In addition, more recent large-scale epidemiological studies have shown discordance of cognition with AD pathology [16–20].”
BackgroundMulticenter clinicopathological correlation in dementia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1476 · Cited by 186 · cited 1×
“Although there is evidence showing that the majority of persons identified as having clinical AD meet the neuropathological criteria for AD [4–8], the correlation between those neuropathological lesions and cognition is relatively poor.”
BackgroundChanges of p53 in the Brains of Patients with Alzheimer's Disease
Kitamura, Y., Shimohama, S., Kamoshima, W., Matsuoka, Y., Nomura, Y., & Taniguchi, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6301 · Cited by 185 · cited 1×
“Consequently, these results have led to intensive research on alterations in DNA repair proteins involved in the repair of such lesions in patients with AD, including p53, PTEN and BRCA1 [28–33].”
ResultEvidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes
Myung, N.-H., Zhu, X., Kruman, I. I., Castellani, R. J., Petersen, R. B., Siedlak, S. L., Perry, G., Smith, M. A., & Lee, H.-G. (2008) · AGE · doi:10.1007/s11357-008-9050-7 · Cited by 170 · cited 1×
“One shows elevated H2AX in hippocampal astrocytes from AD patients (with dementia) in relation to normal controls [73]; another finds no difference in astrocytes or neurons in relation to AD progression [74].”
BackgroundAdult neurogenesis and cellular brain repair with neural progenitors, precursors and stem cells
Shivraj Sohur, U., Emsley, J. G., Mitchell, B. D., & Macklis, J. D. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1887 · Cited by 170 · cited 1×
“Although it is well established that neurons in the adult brain are post-mitotic - except in the hippocampal dentate gyrus and the subventricular zone [96] - neuropathological features of AD, such as the accumulation of Ab and tau, have been shown to be associated with re-entry into the cell-cycle [47,97].”
BackgroundBrazilian Aging Brain Study Group, Grinberg, L. T., de Lucena Ferretti, R. E., Farfel, J. M., Leite, R., Pasqualucci, C. A., Rosemberg, S., Nitrini, R., Saldiva, P. H. N., & Jacob Filho, W. (2007) · Cell and Tissue Banking · doi:10.1007/s10561-006-9022-z · Cited by 169 · cited 3×
“Neuropathological examinations were performed using immunohistochemistry, according to internationally accepted criteria [49].”
MethodInfluentialSelf-citationGao, C., Hölscher, C., Liu, Y., & Li, L. (2012) · revneuro · doi:10.1515/rns.2011.061 · Cited by 164 · cited 1×
“If Akt is not phosphorylated, GSK3-b remains active [93] and is described as responsible for events related to AD pathology, including the hyperphosphorylation of Tau [94].”
BackgroundTransitions to mild cognitive impairments, dementia, and death: findings from the Nun Study
Tyas, S. L., Salazar, J. C., Snowdon, D. A., Desrosiers, M. F., Riley, K. P., Mendiondo, M. S., & Kryscio, R. J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm085 · Cited by 163 · cited 1×
“In addition, more recent large-scale epidemiological studies have shown discordance of cognition with AD pathology [16–20].”
BackgroundChang, C.-J., Mulholland, D. J., Valamehr, B., Mosessian, S., Sellers, W. R., & Wu, H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00310-08 · Cited by 155
The validity of 3 clinical diagnostic criteria for Alzheimer's disease
Kukull, W. A., Larson, E. B., Reifler, B. V., Lampe, T. H., Yerby, M. S., & Hughes, J. P. (1990) · Neurology · doi:10.1212/wnl.40.9.1364 · Cited by 152 · cited 1×
“Although there is evidence showing that the majority of persons identified as having clinical AD meet the neuropathological criteria for AD [4–8], the correlation between those neuropathological lesions and cognition is relatively poor.”
BackgroundLucassen, P., Chung, W., Kamphorst, W., & Swaab, D. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00007 · Cited by 142 · cited 1×
“Some authors have reasoned that the presence of DNA breaks by oxidative damage could be influenced by the post-mortem interval, but the presence of such an effect has not been clearly demonstrated [75–78].”
BackgroundNeuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA)
O'Brien, R. J., Resnick, S. M., Zonderman, A. B., Ferrucci, L., Crain, B. J., Pletnikova, O., Rudow, G., Iacono, D., Riudavets, M. A., Driscoll, I., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1179 · Cited by 137
Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain
Lovell, M. A., Soman, S., & Bradley, M. A. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.08.003 · Cited by 124 · cited 1×
“[72] found a significant increase of hippocampal 8OHdG immunofluorescence in ‘‘preclinical AD’’ individuals compared to normal controls.”
BackgroundCellular, synaptic, and biochemical features of resilient cognition in Alzheimer’s disease
Arnold, S. E., Louneva, N., Cao, K., Wang, L.-S., Han, L.-Y., Wolk, D. A., Negash, S., Leurgans, S. E., Schneider, J. A., Buchman, A. S., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.004 · Cited by 123 · cited 1×
“Some studies have reported preserved neuronal numbers and synaptic densities in the hippocampus in ‘‘preclinical/resilient AD’’ compared with normal and clinical AD cases [62,108,109].”
BackgroundShao, C., Xiong, S., Li, G.-M., Gu, L., Mao, G., Markesbery, W. R., & Lovell, M. A. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.06.003 · Cited by 114 · cited 1×
“Moreover, decreased activity of proteins involved with DNA repair has been reported in MCI subjects [105,106].”
BackgroundNuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons
Zhang, J., Cicero, S. A., Wang, L., Romito-DiGiacomo, R. R., Yang, Y., & Herrup, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711355105 · Cited by 113 · cited 1×
“Another protein (Cdk5), which is not associated with the cell-cycle, has been suggested as a cell-cycle suppressor in post-mitotic neurons [42,43], with ectopic subcellular redistribution in neurons of cases affected with AD [44,45].”
BackgroundSimpson, J. E., Ince, P. G., Haynes, L. J., Theaker, R., Gelsthorpe, C., Baxter, L., Forster, G., Lace, G., Shaw, P. J., Matthews, F. E., et al. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01030.x · Cited by 110 · cited 1×
“One shows elevated H2AX in hippocampal astrocytes from AD patients (with dementia) in relation to normal controls [73]; another finds no difference in astrocytes or neurons in relation to AD progression [74].”
BackgroundDiscriminative and predictive power of an informant report in mild cognitive impairment
Isella, V (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.069765 · Cited by 109 · cited 1×
“The CDR was applied as a semi-structured questionnaire, and this method of application, exclusively with the informant, has been evaluated and published [54].”
MethodAltered Distribution of Cell Cycle Transcriptional Regulators during Alzheimer Disease
Jordan‐Sciutto, K. L., Malaiyandi, L. M., & Bowser, R. P. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.4.358 · Cited by 107 · cited 13×
“Regarding nuclear staining, pyramidal neurons from the hippocampus of CP-AD individuals demonstrated higher expression levels of Cdk4, cyclin D, phospho-Rb, E2F1, Cdk1, and cyclin B than did those from either P-AD or N subjects (Figure 3A, 3C, 3E, 3G, 3I, and 3K; Table 4; Figures S9–S14).”
BackgroundResultInfluentialResistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons
Riudavets, M. A., Iacono, D., Resnick, S. M., O’Brien, R., Zonderman, A. B., Martin, L. J., Rudow, G., Pletnikova, O., & Troncoso, J. C. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.005 · Cited by 106 · cited 1×
“Individuals who have evidence of abundant AD pathology but do not meet clinical criteria for mild cognitive impairment (MCI) or dementia, thus preserving their cognitive functioning, have been described by a range of allied concepts such as ‘‘pathological aging’’, ‘‘preclinical AD’’, ‘‘asymptomatic AD’’, and ‘‘resilie…”
Vascular and metabolic dysfunction in Alzheimer’s disease: a review
Murray, I. V. J., Proza, J. F., Sohrabji, F., & Lawler, J. M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.010355 · Cited by 104 · cited 1×
“Among these factors, oxidative stress has been shown to be involved in AD pathogenesis [64,65].”
BackgroundPost-Mortem diagnosis of dementia by informant interview
Ferretti‐Rebustini, R. E. D. L., Damin, A. E., Brucki, S. M. D., Morillo, L. S., Perroco, T. R., Campora, F., Moreira, E. G., Balbino, E. S., Lima, M. D. C., Battela, C., et al. (2010) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642010dn40200011 · Cited by 99 · cited 1×
“Past medical history, cognitive performance and functional status were determined for each subject [50].”
BackgroundSelf-citationPTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner
Tang, Y., & Eng, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1557 · Cited by 97 · cited 1×
“Under oxidative stress, PTEN accumulates in the nucleus and can bind to p53, amplifying its function [89,90].”
BackgroundCdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex
Zhang, J., Li, H., Yabut, O., Fitzpatrick, H., D'Arcangelo, G., & Herrup, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5628-09.2010 · Cited by 96 · cited 1×
“Studies have proposed that Cdk5 nuclear localization relies on its interaction with p27, and its cell-cycle suppression activity is achieved by direct binding to E2F1, blocking the access of E2F1 to the DNA and thus avoiding the transcription of genes responsible for cell-cycle progression [103,104].”
BackgroundIncreased p27, an essential component of cell cycle control, in Alzheimer's disease
Ogawa, O., Lee, H., Zhu, X., Raina, A., Harris, P. L. R., Castellani, R. J., Perry, G., & Smith, M. A. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00042.x · Cited by 96 · cited 2×
“Furthermore, changes in the expression of cell-cycle proteins (cyclins D [34] and B [34–36], Cdk4 [37], Cdk1 [38], p27 [39], E2F1 [40], and phosphorylated retinoblastoma protein [41]) have been noted in neurons of post-mortem brain specimens from persons with AD.”
BackgroundJorm, A. F. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199709000-00008 · Cited by 96 · cited 3×
“Based on pathological and clinical criteria, subjects were categorized into three groups: I) 19 subjects with neuropathological AD (Braak$IV and CERAD=B or C) and clinical dementia (CDR$2, IQCODE.3.8), termed ‘‘clinical-pathological AD’’ (CPAD); II) 12 subjects with neuropathological AD (Braak$IV and CERAD=B or C) and…”
MethodInfluentialJorm, A. F. (1997) · PubMed · Cited by 92
Ramalho, R. M., Ribeiro, P. S., Solá, S., Castro, R. E., Steer, C. J., & Rodrigues, C. M. P. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02517.x · Cited by 89
Lucassen, P. J., Chung, W. C., Vermeulen, J. P., Van Lookeren Campagne, M., Van Dierendonck, J. H., & Swaab, D. F. (1995) · Journal of Histochemistry & Cytochemistry · doi:10.1177/43.11.7560899 · Cited by 89 · cited 1×
“Some authors have reasoned that the presence of DNA breaks by oxidative damage could be influenced by the post-mortem interval, but the presence of such an effect has not been clearly demonstrated [75–78].”
BackgroundAccumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles
Sonoda, Y., Mukai, H., Matsuo, K., Takahashi, M., Ono, Y., Maeda, K., Akiyama, H., & Kawamata, T. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.12.078 · Cited by 74 · cited 1×
“[31] observed a decrease in nuclear and cytoplasmic staining in brains of Alzheimer’s patients compared to brains of individuals with normal aging.”
BackgroundBRCA1 May Modulate Neuronal Cell Cycle Re-Entry in Alzheimer Disease
Evans, T. A., Raina, A. K., Delacourte, A., Aprelikova, O., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2007) · International Journal of Medical Sciences · doi:10.7150/ijms.4.140 · Cited by 67 · cited 1×
“[33] found elevated levels of BRCA1 in individuals with AD in addition to showing that BRCA1 was co-located with neurofibrillary tangles.”
BackgroundKatsel, P., Tan, W., Fam, P., Purohit, D. P., & Haroutunian, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068361 · Cited by 52 · cited 1×
“Recent studies have reported alterations in DNA repair proteins (cell-cycle checkpoint proteins and tumor suppressors) of pathways involved in the repair of oxidative stress-induced lesions in patients with AD [28,79].”
BackgroundRukhsana Sultana, A., & Butterfield, D. A. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9123-x · Cited by 52 · cited 1×
“Another protein (Cdk5), which is not associated with the cell-cycle, has been suggested as a cell-cycle suppressor in post-mitotic neurons [42,43], with ectopic subcellular redistribution in neurons of cases affected with AD [44,45].”
BackgroundMajd, S., Zarifkar, A., Rastegar, K., & Takhshid, M. A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.04.050 · Cited by 51 · cited 2×
“In fact, the re-expression of cell-cycle proteins in neurons can be induced by treatment with Ab and/or tau protein [97,98].”
BackgroundThakur, A., Siedlak, S. L., James, S. L., Bonda, D., Rao, A., Webber, K. M., Camins, A., Pallàs, M., Casadesús, G., Lee, H., et al. (2008) · PubMed · Cited by 45
Cdk5 and the non-catalytic arrest of the neuronal cell cycle
Zhang, J., & Herrup, K. (2008) · Cell Cycle · doi:10.4161/cc.7.22.7045 · Cited by 44 · cited 1×
“Another protein (Cdk5), which is not associated with the cell-cycle, has been suggested as a cell-cycle suppressor in post-mitotic neurons [42,43], with ectopic subcellular redistribution in neurons of cases affected with AD [44,45].”
BackgroundCyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons
Appert-Collin, A., Hugel, B., Levy, R., Niederhoffer, N., Coupin, G., Lombard, Y., André, P., Poindron, P., & Gies, J. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.01.032 · Cited by 42 · cited 2×
“In addition, cellcycle studies have shown that ectopic expression of cell-cycle markers is associated with neuronal cell death [46–48].”
BackgroundSilva, A. R. T., Grinberg, L. T., Farfel, J. M., Diniz, B. S., Lima, L. A., Silva, P. J. S., Ferretti, R. E. L., Rocha, R. M., Filho, W. J., Carraro, D. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048751 · Cited by 40 · cited 1×
“To uncover the molecular aspects that underlie these pathophysiological processes and resilient brain aging, we performed a gene expression study among subjects with 1) clinical dementia and AD pathology (CPAD), 2) AD pathology and healthy cognition (P-AD), and normal individuals (N) [24].”
MethodSelf-citationHernández‐Ortega, K., Ferrera, P., & Arias, C. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21301 · Cited by 35
DNA-repair in mild cognitive impairment and Alzheimer's disease
Bucholtz, N., & Demuth, I. (2013) · DNA Repair · doi:10.1016/j.dnarep.2013.07.005 · Cited by 34
Hoerndli, F. J., Pelech, S., Papassotiropoulos, A., & Götz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05618.x · Cited by 34 · cited 1×
“In fact, the re-expression of cell-cycle proteins in neurons can be induced by treatment with Ab and/or tau protein [97,98].”
BackgroundCdk5 Levels Oscillate during the Neuronal Cell Cycle
Zhang, J., Li, H., Zhou, T., Zhou, J., & Herrup, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.343152 · Cited by 34 · cited 1×
“Studies have proposed that Cdk5 nuclear localization relies on its interaction with p27, and its cell-cycle suppression activity is achieved by direct binding to E2F1, blocking the access of E2F1 to the DNA and thus avoiding the transcription of genes responsible for cell-cycle progression [103,104].”
BackgroundAhn, K., Joo, Y., Choi, Y., Kim, M., Lee, S. H., Cha, S., Suh, Y., & Kim, H. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21690 · Cited by 25 · cited 1×
“Furthermore, studies have demonstrated an association between Ab treatment/accumulation and neuronal cell death [99–101].”
BackgroundAlzheimer’s Disease: Learning From the Past, Looking to the Future
Barreto, P. D. S. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513488926 · Cited by 12 · cited 1×
“The etiology and pathogenesis of AD is not fully understood, but several factors have been implicated in the progression of AD [63].”
BackgroundPrice (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“Moreover, elevated phosphorylated histone γH2AX (H2A histone family member X) levels have been reported in the hippocampus and lymphocytes from AD patients, indicating an active DNA damage response [230,231].”
BackgroundMicroglial/Macrophage Polarization Dynamics following Traumatic Brain Injury
Kumar, A., Alvarez-Croda, D.-M., Stoica, B. A., Faden, A. I., & Loane, D. J. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4268 · Cited by 339
“inhibition, we assessed H2AX expression in the peri-lesional cortex, which is a marker of oxidative stress-induced DNA damage.(25)”
MethodFragile X-associated tremor/ataxia syndrome — features, mechanisms and management
Hagerman, R. J., & Hagerman, P. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.82 · Cited by 290
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice
Suberbielle, E., Djukic, B., Evans, M., Kim, D. H., Taneja, P., Wang, X., Finucane, M., Knox, J., Ho, K., Devidze, N., et al. (2015) · Nature Communications · doi:10.1038/ncomms9897 · Cited by 202
“2c), consistent with previous reports 13,14 .”
Metadata
- Authors
- Silva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., de Bragança Pereira, C. A., Jacob-Filho, W., & Brentani, H.
- Affiliations
- Universidade de São Paulo (BR)
- AC Camargo Hospital (BR)
- Corresponding author
- Silva, Aderbal R. T.
- Grinberg, Lea T.
- Rocha, Rafael M.
- Carraro, Dirce M.
- Brentani, Helena
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-17
- Volume
- 9
- Issue
- 6
- Pages
- e99897
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4061071
- OpenAlex
- W2129162505
- Cited by
- 99
- References
- 117
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 15 · 2019: 4 · 2018: 13 · 2017: 9 · 2016: 11 · 2015: 7 · 2014: 1
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (11/01652-6, 2011/)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- Alzheimer's disease, oxidative DNA damage, DNA repair, cell cycle regulation, neuronal cell death, postmitotic neurons, hippocampus, 8-hydroxy-2'-deoxyguanosine, H2AX, p53, BRCA1, PTEN, cyclins, cyclin-dependent kinases, p27, E2F1, normal aging
- MeSH terms
- Aged, 80 and over, Alzheimer Disease, Cell Cycle, DNA Damage, DNA Repair, Female, Hippocampus, Humans, Male, Neurons, Apoptosis, Oxidative Stress, Tissue Array Analysis, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.